MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease

Part of paid clinical trials in Chicago, Illinois.

Sponsor
University of Chicago
Study ID
NCT05264051
Status
Recruiting
Apply to this trial

Conditions

  • Liver Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

The purpose of the study is to study the muscle assessment score (MAsS, utilizing MRI, as an objective measure of frailty and muscle composition to serve as a predictor of morbidity and mortality in patients with liver disease.

Key Dates

Start date
Apr 18, 2022
Status verified
Jan 2026
Primary completion
Mar 1, 2027
Completion
Mar 1, 2027

Study Design

Enrollment
1,200 participants (estimated)

Primary Outcome Measure

Waitlist Mortality [ Time Frame: Measured up to 10 years out from enrollment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of ChicagoChicagoIllinois60637
Maria Newsome
[email protected]
773-702-2788
Omar Jamal, MD
[email protected]
773-702-0309
Michael Charlton, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Chicago, IL

By research site
The University of Chicago· Chicago, IL

Related Studies